These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19129449)

  • 1. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.
    Bell MJ; Abbott RJ; Croft NP; Hislop AD; Burrows SR
    J Virol; 2009 Mar; 83(6):2783-8. PubMed ID: 19129449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
    PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP; Thomas WA; Blake NW; Rickinson AB
    Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
    PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.
    Horst D; Burrows SR; Gatherer D; van Wilgenburg B; Bell MJ; Boer IG; Ressing ME; Wiertz EJ
    J Virol; 2012 Jan; 86(1):572-7. PubMed ID: 22013037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.
    Kienzle N; Sculley TB; Poulsen L; Buck M; Cross S; Raab-Traub N; Khanna R
    J Virol; 1998 Aug; 72(8):6614-20. PubMed ID: 9658107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.
    Pepperl S; Benninger-Döring G; Modrow S; Wolf H; Jilg W
    J Virol; 1998 Nov; 72(11):8644-9. PubMed ID: 9765404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.
    Horst D; Favaloro V; Vilardi F; van Leeuwen HC; Garstka MA; Hislop AD; Rabu C; Kremmer E; Rickinson AB; High S; Dobberstein B; Ressing ME; Wiertz EJ
    J Immunol; 2011 Mar; 186(6):3594-605. PubMed ID: 21296983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells.
    Kuzushima K; Hayashi N; Kudoh A; Akatsuka Y; Tsujimura K; Morishima Y; Tsurumi T
    Blood; 2003 Feb; 101(4):1460-8. PubMed ID: 12393434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
    Horst D; van Leeuwen D; Croft NP; Garstka MA; Hislop AD; Kremmer E; Rickinson AB; Wiertz EJ; Ressing ME
    J Immunol; 2009 Feb; 182(4):2313-24. PubMed ID: 19201886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection.
    Kamga L; Gil A; Song I; Brody R; Ghersi D; Aslan N; Stern LJ; Selin LK; Luzuriaga K
    PLoS Pathog; 2019 Nov; 15(11):e1008122. PubMed ID: 31765434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design.
    Bharadwaj M; Sherritt M; Khanna R; Moss DJ
    Vaccine; 2001 Jun; 19(27):3769-77. PubMed ID: 11395212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.